Development of a product in single-dose containers, preservative-free, for the treatment of fungal otitis externa (otomycosis). Two twin phase III clinical trials have been completed in the USA, Mexico, and Europe, which have demonstrated the efficacy and safety of the product. These studies are the basis for worldwide marketing approval, which would constitute the first FDA-approved drug for the treatment of otomycosis.

Topical corticosteroid of medium potency, formulated for the treatment of otic eczema. It is presented in single-dose containers, which makes its administration very convenient for the intended indication.

New moisturizing nasal product, combining well-known efficacious components in a smart polymer formulation, for the relief of dry, irritated nose caused by various conditions, including common cold, sinusitis, allergies, and others. The product will be formulated as a spray, so the ease of use will be a differentiating characteristic compared to most competitors.

New therapeutic entity for the treatment of inflammation and pain that occur after ocular surgery. It is an innovative product since the active ingredient has never been used before in ophthalmology, in single-dose format, and most importantly, formulated with IMPACT-SVT®, a patented nanoemulsion drug delivery technology, which facilitates its therapeutic effect and the tolerability of the product.

Development of an NSAID in single-dose containers, preservative-free, for the treatment of inflammation and pain after ocular surgery. Importantly, the product has never been formulated as a single dose before, so this new project will bring a more convenient administration for the patients.

Development of a combination of prostaglandin analogue and beta-blocker for the treatment of glaucoma. It is being developed in single-dose containers, preservative-free, allowing for a very convenient administration.

Development of a combination of prostaglandin analogue and beta-blocker for the treatment of glaucoma. It is being developed in single-dose containers, allowing for a very convenient administration.

New therapeutic entity with a novel combination of an antibiotic and a corticosteroid for the topical treatment of ocular infections. It will be formulated in single-dose containers. Pre-clinical studies have been performed, and the clinical development phases are expected to be initiated shortly.

New therapeutic entity for the treatment of episodic dry eye disease. It will be formulated in single-dose containers, as a nanoemulsion, using a patented drug delivery technology (IMPACT-SVT®) and allowing for a precise administration with enhanced penetration and high tolerability.

New developmental product for the treatment of moderate to severe chronic dry eye disease. In preliminary animal studies, the results have been very promising, and the clinical phases of the development are expected to be initiated in a short time.

Development of a topical corticosteroid for the treatment of Diabetic Macular Edema, which will be formulated as a topical ophthalmic nanoemulsion in single-dose containers, by using Salvat’s patented technology (IMPACT-SVT®) and allowing for an enhanced penetration for reaching the affected retina.

New therapeutic entity for the treatment of Diabetic Retinopathy. It will be formulated as topical eye drops, in single-dose containers by using Salvat’s patented technology (IMPACT-SVT®) to enhance penetration and reach the patient’s retina.

Bonecure is a cell therapy project, in which allogeneic mesenchymal stem cells subjected to a specific pre-differentiation process are used, for the treatment of patients with post-fracture bone consolidation problems. The cells are applied locally by implanting calcium phosphate supports into which the cells have previously been inoculated.